Prognostic implications of PIK3CA amplification in curatively resected liposarcoma

Joo Hoon Kim, Jae Seok Lee, Eo Jin Kim, Kyu Hyun Park, Ki Hyang Kim, Seong Yoon Yi, Han Seong Kim, Yong Jin Cho, Kyoo Ho Shin, Joong Bae Ahn, Hyuk Hu, Kyung Sik Kim, Young Deuk Choi, Sunghoon Kim, Young Han Lee, Jin Suck Suh, Sung Hoon Noh, Sun Young Rha, Hyo Song Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: We investigated the epidemiologic characteristics and prognostic significance of PIK3CA mutations/amplifications in curative resected liposarcoma. Patients and methods: A total of 125 liposarcoma tissue samples were collected over a 12-year period. PIK3CA mutations and gene copy number amplifications were analyzed by pyrosequencing and fluorescence in situ hybridization (FISH). Results: Nine of the 105 liposarcomas (8.6%) had activating PIK3CA mutation. PIK3CA mutations were more frequent in myxoid/round cell and pleomorphic tumors compared with well-differentiated/dedifferentiated tumors (13.3% vs. 2.2%, P=0.043). In FISH PIK3CA analysis, copy number gain was detected in 14 of the 101 tumors (13.9%): 11 (10.9%) tumors had increased gene copy number (polysomy) and 3 (3.0%) exhibited gene amplification. In survival analysis, patients with PIK3CA copy number gain had a worse prognosis compared to patients without PIK3CA amplification (median disease-free survival [DFS] 22.2 vs. 107.6 months p=0.005). By multivariate analysis, PIK3CA copy number gain was an independent prognostic factor for worse DFS (P=0.027; hazard ratio, 2.400; 95% confidence interval 1.105 to 5.213). PIK3CA mutation was not associated with DFS and overall survival. Conclusions: We demonstrated PIK3CA mutation and amplification in liposarcoma. PIK3CA copy number gain was an independent poor prognostic factor for DFS. Further studies are needed to evaluate the potential diagnostic and therapeutic role of PIK3CA mutations and amplifications in liposarcoma.

Original languageEnglish
Pages (from-to)24549-24558
Number of pages10
JournalOncotarget
Volume7
Issue number17
DOIs
Publication statusPublished - 2016 Apr 26

Fingerprint

Liposarcoma
Mutation
Disease-Free Survival
Gene Dosage
Fluorescence In Situ Hybridization
Neoplasms
Gene Amplification
Survival Analysis
Multivariate Analysis
Confidence Intervals
Survival

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kim, J. H., Lee, J. S., Kim, E. J., Park, K. H., Kim, K. H., Yi, S. Y., ... Kim, H. S. (2016). Prognostic implications of PIK3CA amplification in curatively resected liposarcoma. Oncotarget, 7(17), 24549-24558. https://doi.org/10.18632/oncotarget.8240
Kim, Joo Hoon ; Lee, Jae Seok ; Kim, Eo Jin ; Park, Kyu Hyun ; Kim, Ki Hyang ; Yi, Seong Yoon ; Kim, Han Seong ; Cho, Yong Jin ; Shin, Kyoo Ho ; Ahn, Joong Bae ; Hu, Hyuk ; Kim, Kyung Sik ; Choi, Young Deuk ; Kim, Sunghoon ; Lee, Young Han ; Suh, Jin Suck ; Noh, Sung Hoon ; Rha, Sun Young ; Kim, Hyo Song. / Prognostic implications of PIK3CA amplification in curatively resected liposarcoma. In: Oncotarget. 2016 ; Vol. 7, No. 17. pp. 24549-24558.
@article{19cd2463028f41659078fb17e746d73e,
title = "Prognostic implications of PIK3CA amplification in curatively resected liposarcoma",
abstract = "Background: We investigated the epidemiologic characteristics and prognostic significance of PIK3CA mutations/amplifications in curative resected liposarcoma. Patients and methods: A total of 125 liposarcoma tissue samples were collected over a 12-year period. PIK3CA mutations and gene copy number amplifications were analyzed by pyrosequencing and fluorescence in situ hybridization (FISH). Results: Nine of the 105 liposarcomas (8.6{\%}) had activating PIK3CA mutation. PIK3CA mutations were more frequent in myxoid/round cell and pleomorphic tumors compared with well-differentiated/dedifferentiated tumors (13.3{\%} vs. 2.2{\%}, P=0.043). In FISH PIK3CA analysis, copy number gain was detected in 14 of the 101 tumors (13.9{\%}): 11 (10.9{\%}) tumors had increased gene copy number (polysomy) and 3 (3.0{\%}) exhibited gene amplification. In survival analysis, patients with PIK3CA copy number gain had a worse prognosis compared to patients without PIK3CA amplification (median disease-free survival [DFS] 22.2 vs. 107.6 months p=0.005). By multivariate analysis, PIK3CA copy number gain was an independent prognostic factor for worse DFS (P=0.027; hazard ratio, 2.400; 95{\%} confidence interval 1.105 to 5.213). PIK3CA mutation was not associated with DFS and overall survival. Conclusions: We demonstrated PIK3CA mutation and amplification in liposarcoma. PIK3CA copy number gain was an independent poor prognostic factor for DFS. Further studies are needed to evaluate the potential diagnostic and therapeutic role of PIK3CA mutations and amplifications in liposarcoma.",
author = "Kim, {Joo Hoon} and Lee, {Jae Seok} and Kim, {Eo Jin} and Park, {Kyu Hyun} and Kim, {Ki Hyang} and Yi, {Seong Yoon} and Kim, {Han Seong} and Cho, {Yong Jin} and Shin, {Kyoo Ho} and Ahn, {Joong Bae} and Hyuk Hu and Kim, {Kyung Sik} and Choi, {Young Deuk} and Sunghoon Kim and Lee, {Young Han} and Suh, {Jin Suck} and Noh, {Sung Hoon} and Rha, {Sun Young} and Kim, {Hyo Song}",
year = "2016",
month = "4",
day = "26",
doi = "10.18632/oncotarget.8240",
language = "English",
volume = "7",
pages = "24549--24558",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "17",

}

Kim, JH, Lee, JS, Kim, EJ, Park, KH, Kim, KH, Yi, SY, Kim, HS, Cho, YJ, Shin, KH, Ahn, JB, Hu, H, Kim, KS, Choi, YD, Kim, S, Lee, YH, Suh, JS, Noh, SH, Rha, SY & Kim, HS 2016, 'Prognostic implications of PIK3CA amplification in curatively resected liposarcoma', Oncotarget, vol. 7, no. 17, pp. 24549-24558. https://doi.org/10.18632/oncotarget.8240

Prognostic implications of PIK3CA amplification in curatively resected liposarcoma. / Kim, Joo Hoon; Lee, Jae Seok; Kim, Eo Jin; Park, Kyu Hyun; Kim, Ki Hyang; Yi, Seong Yoon; Kim, Han Seong; Cho, Yong Jin; Shin, Kyoo Ho; Ahn, Joong Bae; Hu, Hyuk; Kim, Kyung Sik; Choi, Young Deuk; Kim, Sunghoon; Lee, Young Han; Suh, Jin Suck; Noh, Sung Hoon; Rha, Sun Young; Kim, Hyo Song.

In: Oncotarget, Vol. 7, No. 17, 26.04.2016, p. 24549-24558.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic implications of PIK3CA amplification in curatively resected liposarcoma

AU - Kim, Joo Hoon

AU - Lee, Jae Seok

AU - Kim, Eo Jin

AU - Park, Kyu Hyun

AU - Kim, Ki Hyang

AU - Yi, Seong Yoon

AU - Kim, Han Seong

AU - Cho, Yong Jin

AU - Shin, Kyoo Ho

AU - Ahn, Joong Bae

AU - Hu, Hyuk

AU - Kim, Kyung Sik

AU - Choi, Young Deuk

AU - Kim, Sunghoon

AU - Lee, Young Han

AU - Suh, Jin Suck

AU - Noh, Sung Hoon

AU - Rha, Sun Young

AU - Kim, Hyo Song

PY - 2016/4/26

Y1 - 2016/4/26

N2 - Background: We investigated the epidemiologic characteristics and prognostic significance of PIK3CA mutations/amplifications in curative resected liposarcoma. Patients and methods: A total of 125 liposarcoma tissue samples were collected over a 12-year period. PIK3CA mutations and gene copy number amplifications were analyzed by pyrosequencing and fluorescence in situ hybridization (FISH). Results: Nine of the 105 liposarcomas (8.6%) had activating PIK3CA mutation. PIK3CA mutations were more frequent in myxoid/round cell and pleomorphic tumors compared with well-differentiated/dedifferentiated tumors (13.3% vs. 2.2%, P=0.043). In FISH PIK3CA analysis, copy number gain was detected in 14 of the 101 tumors (13.9%): 11 (10.9%) tumors had increased gene copy number (polysomy) and 3 (3.0%) exhibited gene amplification. In survival analysis, patients with PIK3CA copy number gain had a worse prognosis compared to patients without PIK3CA amplification (median disease-free survival [DFS] 22.2 vs. 107.6 months p=0.005). By multivariate analysis, PIK3CA copy number gain was an independent prognostic factor for worse DFS (P=0.027; hazard ratio, 2.400; 95% confidence interval 1.105 to 5.213). PIK3CA mutation was not associated with DFS and overall survival. Conclusions: We demonstrated PIK3CA mutation and amplification in liposarcoma. PIK3CA copy number gain was an independent poor prognostic factor for DFS. Further studies are needed to evaluate the potential diagnostic and therapeutic role of PIK3CA mutations and amplifications in liposarcoma.

AB - Background: We investigated the epidemiologic characteristics and prognostic significance of PIK3CA mutations/amplifications in curative resected liposarcoma. Patients and methods: A total of 125 liposarcoma tissue samples were collected over a 12-year period. PIK3CA mutations and gene copy number amplifications were analyzed by pyrosequencing and fluorescence in situ hybridization (FISH). Results: Nine of the 105 liposarcomas (8.6%) had activating PIK3CA mutation. PIK3CA mutations were more frequent in myxoid/round cell and pleomorphic tumors compared with well-differentiated/dedifferentiated tumors (13.3% vs. 2.2%, P=0.043). In FISH PIK3CA analysis, copy number gain was detected in 14 of the 101 tumors (13.9%): 11 (10.9%) tumors had increased gene copy number (polysomy) and 3 (3.0%) exhibited gene amplification. In survival analysis, patients with PIK3CA copy number gain had a worse prognosis compared to patients without PIK3CA amplification (median disease-free survival [DFS] 22.2 vs. 107.6 months p=0.005). By multivariate analysis, PIK3CA copy number gain was an independent prognostic factor for worse DFS (P=0.027; hazard ratio, 2.400; 95% confidence interval 1.105 to 5.213). PIK3CA mutation was not associated with DFS and overall survival. Conclusions: We demonstrated PIK3CA mutation and amplification in liposarcoma. PIK3CA copy number gain was an independent poor prognostic factor for DFS. Further studies are needed to evaluate the potential diagnostic and therapeutic role of PIK3CA mutations and amplifications in liposarcoma.

UR - http://www.scopus.com/inward/record.url?scp=84966603270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966603270&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8240

DO - 10.18632/oncotarget.8240

M3 - Article

C2 - 27016421

AN - SCOPUS:84966603270

VL - 7

SP - 24549

EP - 24558

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 17

ER -

Kim JH, Lee JS, Kim EJ, Park KH, Kim KH, Yi SY et al. Prognostic implications of PIK3CA amplification in curatively resected liposarcoma. Oncotarget. 2016 Apr 26;7(17):24549-24558. https://doi.org/10.18632/oncotarget.8240